3 completed, 2 active not recruiting, 1 recruiting, 1 suspended. 5 Phase 2, 2 Phase 1, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Active not recruiting 2, Completed 1, Recruiting 1, Suspended 1 |
| Phase 1 | 2 | Completed 1, Withdrawn 1 |
| Early Phase 1 | 1 | Completed 1 |
Follow methanesulfonic acid: new trials by email Literature Review of methanesulfonic acid trials Research Report on methanesulfonic acid
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 2 | Active not recruiting | Children's Oncology Group | 1 | 2023-08-14 | 2026-01-09 |
| Enasidenib in Combination With Cobimetinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Cobimetinib, Enasidenib Mesylate - Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 | Completed | City of Hope Medical Center | 3 | 2023-04-28 | 2026-05-05 |
| Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation Bosutinib Monohydrate, Decitabine, Enasidenib Mesylate - Recurrent Acute Myeloid Leukemia | Phase 1 | Withdrawn | City of Hope Medical Center | 2022-06-25 | 2022-06-09 | |
| Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation Enasidenib Mesylate - Acute Myeloid Leukemia | Phase 2 | Suspended | City of Hope Medical Center | 35 | 2019-12-23 | 2026-08-21 |
| CPX-351 Plus Enasidenib for Relapsed AML Enasidenib Mesylate, Liposome-encapsulated Daunorubicin-Cytarabine - Recurrent Acute Myeloid Leukemia | Phase 2 | Active not recruiting | Jonsson Comprehensive Cancer Center | 2 | 2019-04-12 | 2023-09-28 |
| Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation Azacitidine, Enasidenib Mesylate - Acute Bilineal Leukemia, Acute Biphenotypic Leukemia | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 50 | 2018-09-18 | 2026-09-14 |
| The Changes of Urine Growth Factors Level Silodosin - Benign Prostatic Hyperplasia | Early Phase 1 | Completed | En Chu Kong Hospital | 74 | 2013-05-31 | 2024-02-28 |
| Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies Fludarabine phosphate, Busulfan, Total-Body Irradiation - Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With Gene Mutations | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 62 | 2012-12-24 | 2025-10-30 |
Leukemia, Myeloid, Acute (7) · Leukemia, Myelomonocytic, Chronic (2) · Myelodysplastic Syndromes (2) · Anemia, Aplastic (1) · Hodgkin Disease (1) · Leukemia, Biphenotypic, Acute (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myeloid (1) · Lymphoma, Follicular (1) · Lymphoma, Non-Hodgkin (1) · Multiple Myeloma (1) · Polycythemia Vera (1) · Primary Myelofibrosis (1) · Prostatic Hyperplasia (1)
City of Hope Medical Center (3) · Children's Oncology Group (1) · En Chu Kong Hospital (1) · Jonsson Comprehensive Cancer Center (1) · M.D. Anderson Cancer Center (1) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (1)
United States (7) · Canada (1) · Taiwan (1)
Amandeep Salhotra (1) · Brian Ball (1) · Caspian Oliai, MD (1) · Cheng Cheng Wang, M.D Ph.D (1) · Courtney DiNardo (1) · Dolores Grosso, RN, CRNP, DNP (1) · Guido Marcucci (1) · Neal Flomenberg, MD (1) · Sara Zarnegar-Lumley (1)
P30CA033572 (2), U10CA180886 (1)